Results 1 to 10 of about 84,688 (355)

Monte Carlo optimization based QSAR modeling of angiotensin II receptor antagonists

Acta Chimica Slovenica, 2023
The pathogenesis of essential hypertension, congestive heart failure, and reno-vascular hypertension is related to angiotensin II. This study presents QSAR modeling for a set of compounds acting as angiotensin II receptor antagonists based on the Monte ...
Nemanja Nikolić, Tomislav Kostić, Mlađan Golubović, Tamara Nikolić, Marija Marinković, Velimir Perić, Sara Mladenović, Aleksandar Veselinovic   +7 more
doaj   +3 more sources

The impact of new tetralogy drugs on ventricular remodeling in heart failure patients: a systematic review and network meta-analysis. [PDF]

BMC Cardiovasc Disord
Background Heart failure, particularly heart failure with reduced ejection fraction (HFrEF), represents a major global health challenge due to its high prevalence, rapid progression, and substantial mortality rates.
Wang XW, Li H, Wang GQ, Sheng YN, Wang X, Pan H, Wang ZH, Zhang W, Shang YY, Zhong M.   +9 more
europepmc   +2 more sources

Comparative Mortality in Heart Failure on Guideline-Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network. [PDF]

J Am Heart Assoc
Background Guideline‐directed medical therapy (GDMT), including angiotensin receptor‐neprilysin inhibitor, angiotensin‐converting enzyme inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium‐glucose cotransporter‐2 inhibitors, has
Monzo L, Baudry G, Duarte K, Hernandez G, Denquin O, Savarese G, Girerd N.   +6 more
europepmc   +2 more sources

Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension? [PDF]

Vascular Health and Risk Management, 2007
Marc P Maillard, Michel BurnierService of Nephrology, Department of Internal Medicine, Lausanne University Hospital, SwitzerlandAbstract: Blockade of the renin-angiotensin system with selective AT1 receptor antagonists is recognized as an effective mean ...
Marc P Maillard, Michel Burnier
doaj   +2 more sources

Metabolic syndrome and angiotensin II receptor antagonists

Кардиоваскулярная терапия и профилактика, 2007
Aim. To investigate the effects of angiotensin II receptor antagonist irbesartan on blood pressure (BP), tissue insulin sensitivity, carbohydrate and lipid metabolism, cerebral perfusion parameters in patients with arterial hypertension (AH), metabolic ...
K. M. Mamyrbayeva, V. B. Mychka, V. B. Sergienko, I. E. Chazova   +3 more
doaj   +1 more source

Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic

Biomedical Papers, 2022
Aims. Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at angiotensin-converting enzyme inhibitors ...
Renata Aiglova, Milos Taborsky, Marie Lazarova, Ludek Pavlu, Josef Danek, Jan Precek, Alexander Schee, Vit Gloger, Vlastimil Cernicek, Marek Vicha, Tomas Skala   +10 more
doaj   +1 more source

Dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with insufficient glycemic compensation of type 2 diabetes mellitus during 1 year of application of angiotensin II receptor antagonists for hypertension correction. [PDF]

Medičnì Perspektivi, 2014
The purpose of this study was to determine the dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with an insufficient compensation of type 2 diabetes mellitus and hypertension in the correction of blood pressure ...
N. O. Pertseva
doaj   +2 more sources

Difficult choice: angiotensin receptor antagonists

Российский кардиологический журнал, 2013
The paper is focussed on the therapeutic choice of angiotensin receptor antagonists (ARA). The author presents the data on the comparison between different sartans and their benefits which are not explained by the blood pressure reduction.
E. O. Taratukhin
doaj   +1 more source

Drug treatment of hypertension: focus on vascular health [PDF]

, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C., Lang, Ninian N., Touyz, Rhian M.   +2 more
core   +1 more source

The orphan receptor GPR35 contributes to angiotensin II–induced hypertension and cardiac dysfunction in mice [PDF]

, 2018
BACKGROUND: The orphan receptor G protein–coupled receptor 35 (GPR35) has been associated with a range of diseases, including cancer, inflammatory bowel disease, diabetes, hypertension, and heart failure.
Divorty, Nina, Graham, Delyth, Milligan, Graeme, Nicklin, Stuart A.   +3 more
core   +1 more source